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METHODS OF PROMOTING ANGIOGENESIS 
USING CERIUM OXIDE NANOPARTICLES 
CROSS-REFERENCE TO RELATED 
APPLICATION 
Priority is claimed to provisional patent application Ser. 
2 
Blood vessels are surrounded by biological tissue in an 
extracellular matrix. The formation of new blood vessels is a 
function of the interactions between endothelial cells and the 
interaction of the endothelial cells with the extracellular 
matrix. These interactions are regulated by receptors on the 
surface of endothelial cells, which are sensitive to particular 
molecules such as angiogenic growth factors. 
No. 61/493,994 titled "Pro-angiogenic properties of cerium 
oxide nanoparticles: Role of surface Ce3+/Ce4 + ratio on 
induction of tube formation," which was filed Jun. 7, 2011 and 
is incorporated herein by reference in its entirety. 
Angiogenesis can also be promoted chemically by apply-
ing non-endogenous compounds. For example, Eu(III) 
10 hydroxide nanorods are reported to have pro-angiogenic 
properties. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
Cerium oxide nanoparticles exhibit interesting physical 
behavior, which has been exploited for various biological 
applications. Cerium oxide nanoparticles are typically con-
This invention was made with govermnent support under 
grant 1R01AG031529-01 awarded by the National Institutes 
of Health and under grants 0708172 CBET and 080473355 
CBET awarded by the National Science Foundation. The 
govermnent has certain rights in the invention. 
15 sidered to be antioxidants since they have been shown to 
scavenge reactive oxygen species or reactive oxygen inter-
mediates. The antioxidant properties of cerium oxide nano-
particles are believed to be a function of the fact that, at the 
surface of the nanoparticles, cerium can be reversibly oxi-
20 dized from a +3 state to a naturally stable +4 oxidation state. 
SEQUENCE LISTING 
Antioxidants typically inhibit, rather than promote, angio-
genesis. Accordingly, the conventional wisdom on cerium 
oxide nanoparticles would suggest that they inhibit angiogen-
esis. Remarkably, the present inventors have unexpectedly 
25 found that cerium oxide nanoparticles also promote angio-
genesis and are useful for treating physiological conditions 
that require the growth of new blood vessels in order to 
remediate the condition. 
This application contains a Sequence Listing electroni-
cally submitted via EFS-web to the United States Patent and 
Trademark Office as a text file named "Sequence Listing.txt." 
The electronically filed Sequence Listing serves as both the 
paper copy required by 37 C.F.R. §1.821(c) and the computer 
readable file required by 37 C.F.R. §1.821(c). The informa-
tion contained in the Sequence Listing is incorporated herein 30 
by reference in its entirety. 
FIELD OF THE INVENTION 
The invention relates to promoting angiogenesis and, more 35 




In view of the foregoing, it is an object of the invention is to 
provide methods of promoting angiogenesis using cerium 
oxide nanoparticles. 
In certain methods of the invention cerium oxide nanopar-
ticles are used to promote angiogenesis in animal tissue. In 
such methods, angiogenesis is promoted in the tissue by 
contacting the tissue with a composition comprising cerium 
oxide nanoparticles effective for stimulating proliferation of 
40 endothelial cells associated with the tissue. 
Angiogenesis is an important physiological process in 
which new blood vessels form from pre-existing blood ves-
sels. Compounds that target angiogenesis offer a route to 
treating diseases characterized by poor or abnormal vascular-
ization of biological tissue. Abnormal angiogenesis can trig- 45 
ger pathological conditions such as cancer, chronic inflam-
mation, diabetic retinopathy and arthritis. Insufficient 
angiogenesis is a major pathological component of chronic 
wounds or ischemic heart diseases. 
Compounds aimed at treating diseases related to angiogen- 50 
esis typically either inhibit or induce the creation of new 
blood vessels. Angiogenesis inhibitors are used to prevent 
new blood vessels from forming in areas where blood vessels 
should not form. In contrast, angiogenesis promoters are used 
in areas where the tissue requires new blood vessels to per- 55 
form essential functions such as repairing wounds. Neo-vas-
cularization should be promoted in such areas in order to 
transport nutrients to the site. 
Angiogenesis can be promoted chemically by various 
endogenous angiogenic growth factors such as vascular 60 
endothelial growth factor ("VEGF") and fibroblast growth 
factor ("FGF"). VEGF-A and bFGF have been proposed to 
increase the blood flow to the damaged area. Cells called 
"endothelial cells" line mature blood vessels and typically do 
not proliferate. However, if endothelial cells are activated by 65 
an angiogenic growth factor, they will proliferate and migrate 
into un-vascularized tissue to form new blood vessels. 
In certain methods of the invention cerium oxide nanopar-
ticles are used to promote angiogenesis in a patient having a 
physiological condition that can be remediated by increasing 
endothelial cell proliferation by administering the cerium 
oxide nanoparticles to the patient. 
In certain methods of the invention cerium oxide nanopar-
ticles are used to promote angiogenesis in a patient having a 
condition that can be remediated by increasing endothelial 
cell proliferation by contacting the a tissue of the patient with 
cerium oxide nanoparticles in an amount sufficient to tran-
siently lower the intracellular oxygen concentration of the 
tissue, wherein the transient lowering of the intracellular oxy-
gen concentration stimulates expression ofHIFla, promotes 
proliferation of endothelial cells, and promotes angiogenesis 
in the tissue. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
Office upon request and payment of the necessary fee. 
FIGS. lA-D show the characterization of cerium oxide 
nanoparticles (CNPs). A shows HRTEM image of the differ-
ently synthesized CNPs (CNP-I & CNP-II), having similar 
shape and size (3-5 nm). The selected area electron diffraction 
(SAED) pattern in the inset of A confirms the fluorite struc-
US 8,951,539 Bl 
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ture where A (100), B (200), C (220), D (311) are the crystal 
plane of the lattice. B shows the XPS spectrum of CNP-I and 
CNP-II. C and D show deconvoluted XPS spectra of CNP-I 
and CNP-II. E shows the zeta potential of CNP-I and CNP-II. 
FIG. 2 shows representative HRTEM images of the differ- 5 
ent shaped and sized CNPs discussed in the examples section. 
FIGS. 3A-D show the assessment of cell viability in 
HUVECs exposed to CNPs. HUVEC cells were cultured in 
endothelial cell media (ScienceCell, San Diego, Calif., USA) 
supplemented with 5% FBS and 100 IU ml-1 penicillin, and 10 
MTT dye reduction was assessed after 24 h (A) and 48 (B) 
treatment with varying concentrations of CNP-I and CNP-II. 
C and Dare graphs that show the cell viability of cells treated 
with different size (10-15 nm), 15-20 nm, >25 nm and 30-50 
nm) and shaped (star-shaped and rod-shaped) CNPs at 1000 15 
nM concentration after 24 hr and 48 hr of incubation, respec-
tively. The data are reported as the mean of multiple indepen-
dent cultures and the error represents standard deviation. 
FIGS. 4A-G show that CNPs promote angiogenesis in 
HUVEC cell culture models. HUVEC cells were cultured 20 
with vehicle (control), 10 µM ~-estradiol (negative control), 
30 ng rVEGF (positive control) and varying concentrations of 
cerium oxide nanoparticles (100 nM to 1 µM CNP-I or CNP-
II) and tube formation counted as the number of branches at 
1 Ox magnification after 8 hr of treatment. The data represent 25 
the mean of at least six different experiments and the plotted 
error represents the standard deviation. A and B show the 
number of tubes formed when cells were exposed to different 
concentrations of CNP-I and CNP-II respectively. Images of 
tubes formed in beta-estradiol (C), control (D), VEGF treated 30 
(E), 1 µM CNP-I treated (F) and 1000 nM CNP-II treated (G) 
after 8 hr of incubation are shown. 
FIGS. SA-D shows the effect of the Ce3 +/Ce4 + ratio, zeta 
potential, size and shape of CNPs on tube formation. Tube 
formation in (A) CNP-I (Ce3+/Ce4 + ~ 1.33), CNP-II (Ce3 +/ 35 
Ce4 + ~o.37) and Si02 ; (B) CNP with different zeta poten-
tials: CNP-I (+17.78±0.5 mV), CNP-I' (-20±1.4 mV), CNP-
II (-14.05±0.83 mV) and CNP-II' ( +34.05±0.52 mV); (C) 
CNPs with varying size; (D) CNPs with varying shape.All the 
experiments were carried out with cells exposed to nanopar- 40 
ticles at a concentration of 1 µM. The data represent a mean of 
at least six experiments and the error plotted represents the 
standard deviation. 
FI GS. 6A-D show CNP induced angiogenesis measured by 
Chick CAM assay. The extent of angiogenesis on CAM's 45 
treated with either (A) methylcellulose, (B) 50 ng ofVEGF-
4 
dative stress, hemeoxygenase 1 (E) and thioredoxin reductase 
(F) with or without CNP-I are shown. 
FIGS. 9A-D showthatCNPsregulateofHIFla by altering 
the intracellular oxygen concentration. Analysis ofHIFla in 
cytoplasmic (A) and nuclear (B) fractions at different time 
points (0 min, 30 min and 2 hr) in cells treated with 1 µM 
CNP-I or CoC12 used as a positive control (2 hr). Semi-
quantitative data obtained by densitometric analysis are pre-
sented as mean±standard deviations from two independent 
experiments. The bar diagram is the fold ofHIFl a amount as 
normalized to the ~-actin expression. C shows the immunof-
luorescence image (left to right: Blue-DCF, Green-pimonida-
zole staining and merge image) of control and CNP treated 
HUVEC cells for different time durations (0 min, 30 min, 2 
hr). The semi-quantitative data (D) calculated by measuring 
the fluorescence intensity of cells and presented as 
mean±standard deviations. 
FIG. 10 shows immunoblot detection of HDAC-1 Ill 
nuclear and cytoplasmic extracts from HUVEC cells. 
HUVEC cells were treated with CoC12 (2 h) or 1000 nM 
CNPs for two different time durations (30 min and 2 hr). 
Nuclear and cytoplasmic lysates were prepared from treated 
and untreated cells and analyzed for enrichment of the 
nuclear marker protein HDAC-1. In all cases, nuclear extracts 
show an enhancement of nuclear proteins. Here, N=nuclear 
lysate and C=cytoplasmic lysate. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
In the Summary above and in the Detailed Description of 
Preferred Embodiments, reference is made to particular fea-
tures (including method steps) of the invention. It is to be 
understood that the disclosure of the invention in this speci-
fication includes all possible combinations of such particular 
features. For example, where a particular feature is disclosed 
in the context of a particular aspect or embodiment of the 
invention, that feature can also be used, to the extent possible, 
in combination with and/or in the context of other particular 
aspects and embodiments of the invention, and in the inven-
tion generally. 
The term "comprises" is used herein to mean that other 
features, ingredients, steps, etc. are optionally present. When 
reference is made herein to a method comprising two or more 
defined steps, the steps can be carried in any order or simul-
taneously (except where the context excludes that possibil-
ity), and the method can include one or more steps which are 
carried out before any of the defined steps, between two of the 
A, (C) 1 µg ofCNPl or (D) 1 µg ofCNP2. (E) The extent of 
CAM angiogenesis measured by counting the number of 
vascular sprouts from tertiary vessels in a minimum of 8 
separate experiments. Hpf means high power field. 50 defined steps, or after all of the defined steps (except where 
the context excludes that possibility). FIGS. 7A-C show that CNPs induced VEGF expression. 
(A) The amount of VEGF released from HUVEC cells to 
culture supernatant (exposed to varying concentrations of 
CNP-I) were measured by using ELISA. (B) The intracellular 
VEGF levels from HUVEC cells after CNP-I treatment (for 55 
different time points) was analyzed using the western blot 
technique. Semi-quantitative data obtained by densitometric 
analysis of western blot images are presented as 
mean±standard deviation from multiple experiments. (C) 
Changes in HUVEC cell m-RNA level after CNPI treatment 60 
were determined by RT-PCR. 
FIGS. SA-D show that reactive oxygen species are not 
generated in HUVECs during CNP-I exposure. DCFH2 -DA 
(green, used for estimate ROS)/DAPI (blue, used for nuclear 
staining) staining were used. A, B, C and D are control, 65 
positive control, 30 ng VEGF and CNP-I respectively. Time 
dependent expression levels of two markers of cellular oxi-
This invention may be embodied in many different forms 
and should not be construed as limited to the embodiments set 
forth herein. Rather, these embodiments are provided so that 
this disclosure will be thorough and complete, and will con-
vey the scope of the invention to those skilled in the art. 
Embodiments of the invention involve the use of cerium 
oxide nanoparticles for promoting angiogenesis. A particular 
embodiment is a method of promoting angiogenesis in animal 
tissue. The method comprises contacting the tissue with a 
composition comprising cerium oxide nanoparticles effective 
for stimulating proliferation of endothelial cells associated 
with the tissue. Animal tissue includes but is not limited to 
living or artificial manimalian or non-manimalian tissue that 
is capable of being vascularized. The animal tissue is prefer-
ably a tissue for which neovascularization would provide a 
benefit, such as damaged tissue that needs neovascularization 
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to heal, as opposed to a tissue in which neovascularization is The cerium oxide nanoparticles may be mixed with other 
to be avoided, such as certain cancerous tissues. substances to provide a pharmaceutically acceptable dosage 
Contacting the tissue with the composition may be form. Examples of these substances include one or more 
achieved by bringing or putting the composition into a state or excipients, diluents, disintegrants, emulsifiers, solvents, pro-
condition of touching the tissue or being in immediate or local cessing aids, buffering agents, colorants, flavorings, solvents, 
proximity to the tissue. Examples of techniques for contact- coating agents, binders, carriers, glidants, lubricants, granu-
ing the tissue include conventional techniques for adminis- Iating agents, gelling agents, polishing agents, suspending 
tering pharmaceutical substances such as, for example, intra- agent, sweetening agent, anti-adherents, preservatives, emul-
venous, pericardia!, oral, via implant, transmucosal, sifters, antioxidants, plasticizers, surfactants, viscosity 
transdermal, intramuscular, subcutaneous, intraperitoneal, 10 agents, enteric agents, wetting agents, thickening agents, sta-
intrathecal, intralymphatical, intralesional, epidural, or topi- bilizing agents, solubilizing agents, bioadhesives, film form-
cal administration techniques. ing agents, essential oils, emollients, dissolution enhancers, 
"Stimulating proliferation of endothelial cells" means that dispersing agents, or combinations thereof. 
the cerium oxide nanoparticles are, at least in part, respon- The cerium oxide nanoparticles may be spherical, rod-
sible for increasing the number of endothelial cells in the 15 shaped, star-shaped, or polygonal. As discussed in the 
tissue. The increased number of endothelial cells allows for examples section, the shape of the cerium oxide nanoparticles 
neovascularization of the tissue. Remarkably, the data dis- apparently has little effect on their ability to promote angio-
cussed in the examples section show that cerium oxide nano- genesis with the exception being that the rod-shaped cerium 
particles can stimulate a 400% increase in angiogenesis when oxide nanoparticles resulted in a slightly decreased endothe-
compared to a control sample. 20 lial cell proliferation. 
Another particular embodiment of a method for promoting In a preferred embodiment, the cerium oxide nanoparticles 
angiogenesis comprises administering ceriumoxidenanopar- are spherically-shaped, meaning that they more or less 
ticles to a patient having a physiological condition that can be approximate the shape of a sphere. Preferably, the average 
remediated by increasing endothelial cell proliferation. The diameter of the spherically-shaped cerium oxide nanopar-
term "administering" means the giving or applying of a sub- 25 ti cl es is about 15 nm or less, about 1 nm to about 15 nm, about 
stance, including in vivo and/or ex vivo administration. Com- 2 nm to about 6 nm, or about 3 nm to about 5 nm. In a 
positions may be administered systemically either orally, particularly preferred embodiment, the spherically-shaped 
buccally, parenterally, topically, by inhalation or insuffiations cerium oxide nanoparticles have an average diameter of3 nm 
(i.e., through the mouth or through the nose), or rectally in to 5 nm as measured by transmission electron microscopy. In 
dosage unit formulations containing conventional pharma- 30 embodiments in which the cerium oxide nanoparticles are not 
ceutically acceptable carriers, adjuvants, and vehicles as spherically shaped, it is preferred that the average dimension 
desired, or may be locally administered by means such as, but between two opposing sides of the nanoparticles is 15 nm or 
not limited to, injection, implantation, grafting, topical appli- less. 
cation, or parenterally. Administering can be performed, for The cerium oxide nanoparticles have a cerium oxide core 
example, once, a plurality of times, and/or over one or more 35 with an external surface. The surface is characterized accord-
extended periods. ing to the percentage of Ce(3+) relative to Ce( 4+) ions 
The term "physiological condition" means any abnormal thereon. Although the amount is not intended to be limiting, 
physical or physiological condition characterized, at least in when used in methods of the invention, some preferred ranges 
part, by a need for neovascularization in order to remediate of Ce(3+ ):Ce( 4+) percentages are: about 80%:20% to about 
the condition. Examples of such conditions include, but are 40 20%:80%, about 75%:25% to about 25%:75%, about 60%: 
not limited to: wounds and ischemic conditions where insuf- 40% to about 25%:75%, or about 57%:43% to about 27%: 
ficient angiogenesis is the main cause of the pathology. 73%. In certain preferred embodiments, the percentage of 
A "patient" is a human or other animal subject that has the Ce(3+) relative to Ce( 4+) is >50% Ce(3+ ). 
physiological condition. Examples of patients include, but The concentration of cerium oxide in the composition that 
are not limited to manimalian subjects such as humans, mice, 45 is administered to the patient or used to contact the tissue can 
rats, dogs, pigs, rabbits, monkeys, or apes. Examples of be varied according to the type of administration or tissue 
patients also include, but are not limited to non-mammalian being contacted. In preferred embodiments, the cerium oxide 
subjects such as chickens, for example. concentration in the composition is between about 0.5 µM to 
Another particular embodiment of a method of promoting about 1.5 µM. In other preferred embodiments, the cerium 
angiogenesis involves promoting angiogenesis in a patient 50 oxide concentration in the composition is about 1 µM. 
EXAMPLES 
having a condition that can be remediated by increasing pro-
liferation of endothelial cells. In this embodiment, the method 
comprises contacting a tissue of the patient with cerium oxide 
nanoparticles in an amount sufficient to transiently lower an 
intracellular oxygen concentration of the tissue, wherein the 
transient lowering of the intracellular oxygen concentration 
stimulates expression ofHIF la and promotes proliferation of 
endothelial cells in the tissue. 
The following examples are provided for the purpose of 
55 illustration and do not limit the scope of the invention in any 
way. 
Example 1 
Preparation and Characterization of Cerium Oxide 
Nanoparticles 
In effect, contacting the tissue with the cerium oxide nano-
particles leads to a transient or short term decrease in the 60 
intracellular oxygen environment of the tissue. This, in tum, 
stimulates the expression of the angiogenic growth factor 
HIFl a, which promotes proliferation of endothelial cells and 
promotes angiogenesis. 
This example discusses the preparation and characteriza-
tion of cerium oxide nanoparticles used in the subsequent 
65 examples. Details about the cerium oxide nanoparticles and cerium 
oxidenanoparticles compositions useful in the methods of the 
invention are now described. 
Cerium oxide nanoparticles were prepared according to 
two different synthetic protocols. In either protocol 99.999% 
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pure cerium nitrate hexahydrate purchased from Sigma Ald-
rich was used as a precursor reagent. 
In the first synthetic protocol, the cerium oxide nanopar-
ticles referred to herein as (CNP-I) were prepared using the 
wet chemical method described in an article titled "Anti- 5 
inflammatory Properties of Cerium Oxide Nanoparticles," 
published in Small 2009 5(24) at pages 2848-2856. The por-
tion of this article that describes the synthesis of cerium oxide 
nanoparticles is incorporated herein by reference. 
In the second synthetic protocol, the cerium oxide nano- 10 
particles referred to herein as (CNP-II) were prepared using a 
conventional NH4 0H precipitation method. Briefly, cerium 
nitrate hexahydrate was dissolved in deionized sterile water. 
A stoichiometric amount NH40H was added to the cerium 
nitrate solution and was stirred for about 4 hr at room tern- 15 
perature. The cerium oxide nanoparticles that formed were 
subsequently separated from the solution by centrifugation at 
about 8000 g for about 10 minutes. 
8 
Proliferation of endothelial cells is the first step involved in 
angiogenesis. Proliferation of the human umbilical vein 
endothelial cells (HUVECs) was estimated using the tetrazo-
lium dye reduction (MTT) assay. No cytotoxicity was 
observed in cells exposed to eitherof the CNPs (FI GS. 3A and 
B). Cell proliferation was also analyzed in the presence of 
different size and shaped cerium oxide nanoparticles at a 
concentration of 1 µM (FIGS. 3C and D). With the exception 
of cerium oxide nanorods, other size and shaped nanopar-
ticles did not reveal any overt toxicity towards HUVEC cells. 
Exposure to cerium oxide nanorods led to a slight reduction in 
cell proliferation (P>0.05). 
The endothelial tube formation assay is an in vitro model 
system where anti and pro-angiogenic molecules can be 
tested. FIG. 4 (A) shows the representative tube formation of 
the control, positive control (30 ng VEGF), negative control 
(10 pM 2-methoxyestradiol) and different concentrations of 
CNP-I exposure. Interestingly, we observed that the addition 
of CNP-I to cells resulted in a significant, concentration 
dependent, (P: -S; O.OOI; induction 40% of tube increase) 
formation. Further, up to 1 pM concentration increases of 
CNP-I up to 10 pM did not increase tube formation signifi-
cantly (data not shown). A weaker induction of tube forma-
tion was seen (P: -S; 0. 05; increase) with the addition of 
The size and morphology of the nanoparticles were ana-
lyzed using high resolution transmission electron microscopy 20 
(HRTEM), with a FEI Tecnai F30 having an energy dispersive 
X-ray (EDX) analyzer. The oxidation states of the cerium on 
the surface of the nanoparticle were calculated using a 5400 
PHI ESCA (XPS) spectrometer and Mg-Ka X-radiation 
(1253.6 eV) at a power of350 W. 25 CNP-II (FIG. 4B.). 
As shown in FIG. lA, the size of the CNP-I and CNP-II 
nanoparticles were typically about 3 to about 5 nm. For some 
experiments different sized nanoparticles were used, how-
ever. Cerium oxide nanoparticles having a size of about 10 nm 
to about 15 nm were purchased from from Alfa Aesar, Inc. 30 
Cerium oxide nanoparticles having a size of about 15 nm to 
about 20 nm were purchased from Nanostructure and Amor-
phous Inc. Cerium oxide nanoparticles having a size of 
about >25 nm were purchased from Sigma Aldrich, Inc. 
Cerium oxide nanoparticles having a size of about 50 nm to 35 
about 60 nm were purchased from Johnson Matthey, Pie. 
One difference between CNP-I and CNP-II is that CNP-I 
and CNP-II include different ratios of Ce3 +/Ce4 + on their 
surfaces. FIGS. lB and C show the Ce (3d) XPS spectrum of 
CNP-I and CNP-II. CNP-I has a high Ce3 + concentration 40 
(57%) as compared to CNP-II (27%). The Ce3+ concentration 
was calculated as described in an article titled "Symmetry-
Driven Spontaneous Self-Assembly of Nanoscale Ceria 
Building Blocks to Fractal Superoctahedra" published in 
Crystal Growth & Design 2009 9(3) at pages 1614-1620. The 45 
portion of that article describing how to calculate the concen-
tration of cerium ions is incorporated by reference herein. 
To confirm that tube formation induction is a unique prop-
erty of CNPs, a similar sized Si02 nanoparticle (5-10 nm; 
FIG. 2) was tested and no tubes were observed (FIG. SA). We 
also determined Lipopolysaccharide (LPS) contamination, 
because low levels of LPS may influence the tube formation 
assay. LPS was not detected using either of the CNPs ( <0.005 
EU/ml), showing that induction of tube formation is an intrin-
sic property ofCNPs. 
To determine whether the promotion of endothelial tube 
formation is a function of surface charge, we tested the effect 
of tube formation using CNP-I and CNP-II with inverted 
surface charge by treating the CNP-I and CNP-II with acid (1 
mM HCL) or base ( 1 mM N aO H) while stirring for about 4 to 
about 6 hrs. After thorough washing with dH20, the inverted 
zeta potential of CNP-I* and CNP-II* was altered to -20±1.4 
mV and +44.08±1.1 mV, respectively. We did not notice a 
difference between the promotion of tube formation when 
cells were treated with the original CNPs or the CNPs with 
inverted zeta potentials (FIG. SB). 
We also determined whether the endothelial cell culture 
medium (ECM) influenced the surface charge of CNP-I and 
CNP-II. CNP-I and CNP-II were analyzed after 1 hr incuba-
tion in ECM in the absence of cells. Both types of nanopar-
ticles showed a net negative surface charge of about 
Another difference between CNP-I and CNP-II is that the 
surface charge of the nanoparticles has a different polarity. 
The surface charge is quantified using a parameter called a 
Zeta potential. The Zetapotentials of CNP-I and CNP-II are 
+17.78±0.5 and -14.05±0.83 mV, respectively, as shown in 
FIG. lD. 
50 -9.23±0.56 mV. This suggests that CNPs interact with com-
ponents ofECM, thereby shifting the surface charge towards 
the negative. Our combined results indicate that surface 
charge does not influence tube induction. 
Cerium oxide nanoparticles with different shapes includ-
ing stars, polygons, and nanorods have also been synthesized 
and confirmed by HRTEM (FIG. 2). 
In the following examples, the cerium oxide nanoparticles 
samples were diluted in either phosphate buffer, saline solu-
tion, or cell culture media to the concentration indicated. 
Example 2 
CNP-I and CNP-II Induce the Formation of 
Endothelial Tubes 
This example shows that cerium oxide nanoparticles pro-
mote proliferation of endothelial cells. 
To determine possible size and shape effects, CNPs span-
55 ning: 3-5, 10-15, 15-20, >25 and 50-60 nm were exposed to 
HUVECS at a concentration of 1 µM. As shown in FIG. SC, 
the 3-5 nm and 10-15 nm sized CNPs showed induced tube 
formation while exposing HUVECS to CNPs > 15 nm in size 
did not result in tube formation. The micron size particles 
60 inhibited tube formation, though the inhibition was not sta-
tistically significant. 
The size modulation may be linked to a change in the 
mechanism by which the cells interact with the CNPs. To 
eliminate this possibility, HUVECs were exposed to different 
65 shaped CNPs all having a size> 15 nm. No discernible differ-
ence in tube formation was observed as a function of shape 
(FIG. SD). 




increase in ROS generation was observed in CNP-I treated 
cells (green-DCF positive) after 2 hr of CNP-I treatment. To 
further confirm, we analyzed the mRNA expression of 
hemeoxygenase-1 (HO 1) and thioredoxin reductase (TrxRl ), 
CNP-I and CNP-II Promote Mature Vascular 
Sprouting in Chick Chorioallantoic Membrane 
(CAM) Sprouting Assay 
This examples shows that cerium oxide nanoparticles pro-
mote vascular sprouting. 
5 which is upregulated during oxidative stress. No increase in 
H0-1 or TrxRl expression was observed up to 4 hr after 
addition of CNPs (FIG. SC). These results indicate that expo-
sure to CNPs most likely does not induce the angiogenesis by 
triggering higher levels of ROS, unlike Eu(OH)3 nanorods To support our observations using tube assays, we per-
formed chick CAM sprouting assays. FIG. 6A-D represent 
the CAM after treatment with vehicle (A), VEGF (positive 
control) (B), 1 µM CNP-I (C) or 1 µM CNP-II (D). No 
vascular sprouting was observed when CAMs were treated 
with water only (control). Vascular sprouting was observed 
with CAMs, treated with VEGF (50 ng), as expected. The 15 
CAMs treated with CNP-I and CNP-II remarkably showed 
significant vascular sprouting. CNP-I promoted angiogenesis 
(Ps0.001) with matured vascular sprouting. CNP-II 
(Ps0.001) also presented similar angiogenesis but was 
slightly less robust compared to CNP-I. Quantitative data 20 
from the CAM assay is shown in FIG. 6E and reveals that 
CNP-I induces a 400% increase in angiogenesis compared to 
the un-stimulated control. Our results clearly demonstrate 
that CNPs induce endothelial cell proliferation as well as 
vascular sprouting. 
10 which have been shown to induce angiogenesis through ROS 
generation. 
Angiogenesis can be regulated by the local oxygen con-
centration of the tissue. This pathway is indirectly governed 
by HIF 1 a regulation and transcriptional activation of angio-
genic factors, which regulates gene expression involved in 
angiogenesis. We estimated the amount ofHIFla in the cyto-
plasm and the amount translocated into the nucleus of 
HUVECs following CNPI treatment. FIGS. 9A and B present 
the amount ofHIFla in cytoplasmic and nuclear fraction in 
control, CNP-I and CoC12 (Positive control) treated cells (30). 
A higher amount of HIFla in cytoplasmic fraction was 
observed in cells treated with CNP-I (both 30 min and 2 hr 
treatment) (FIG. 9A). As expected, HIFla nucleartransloca-
tion was also found to be increased in CNP-I treated cells 
Example 4 
Cerium Oxide Nanoparticles Promote Angiogenesis 
Through a VEGF Regulated Pathway, by Regulating 
the Intracellular Oxygen Environment, and by 
Promoting Expression ofHIFla 
25 (FIG. 9B). FIG. 10 shows the immunoblotting of nuclear 
marker histone deacetylase (HDAC-1 ), which confirmed suc-
cessful separation of nuclear and cytoplasmic fraction of 
CNPI treated cells. HIFla stabilization and translocation to 
the nucleus indicates that CNPs induced angiogenesis by 
30 regulating HIFla. 
Conventional immunostaining with pimonidazole was 
used to determine the intracellular 0 2 level. Immunostaining 
images representing the intracellular 0 2 level at different 
times (30 min, 1hrand2 hr) after CNP-I treatment are shown This example shows that cerium oxide nanoparticles pro-
mote angiogenesis through a VEGF regulated pathway, by 
regulating the intracellular oxygen environment, and by 
stimulating the expression ofHIFla. 
Next, we analyzed VEGF expression in a culture medium 
35 in FIG. 9C. FIG. 9D shows quantitative immunofluorescence 
data, which is proportional to the amount of 0 2 . Interestingly, 
low 0 2 levels were observed immediately after CNP-I treat-
ment up to 1 hr, however 0 2 levels returned to normal after 2 
hr of CNP-I treatment. This supports our hypothesis that of HUVEC cells by ELISA (FIG. 7A). Specifically, we 
focused on HUVECs exposed to CNP-I to further understand 
the molecular mechanism underpinning the angiogenic prop-
erties of the CNPs. A significant increase in VEGF levels in 
the culture medium for CNP-I treated cells was observed. The 
amount ofVEGF reached a maximum when the cells were 
exposed to a concentration of 1 µM CNP-I. In comparison, the 45 
amount of excreted VEGF was less when a 2 µM CNP con-
centration was used. This suggests that a CNP concentration 
40 CNPs activate HIFla by modulation intracellular 0 2 level. 
Experimental Techniques 
Cell Cultures. 
HUVEC cells were obtained from Lonza Walkersville, Inc 
(Walkersville, Md., USA). HUVEC calls were grown in 
Endothelial Basal Media-2 (Lonza Walkersville) containing 
2% FBS. Cultures were maintained at 37° C. and 5% C02 in 
humidified incubator and only passages 3-6 were used for 
of about 1 µM the optimum or, at least, close to the optimum 
concentration of CNPs for stimulating angiogenesis induc-
tion. 50 experiments. 
Cell Viability Assay. 
The proliferation ofHUVEC were assayed by colorimetric 
assay using MTT (3-( 4,5 dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) dye. Cells were cultured in 96-well 
55 plate at a density of3xl 03 cells/well. Then cells were treated 
The intracellular VEGF expression in CNP treated cells 
was estimated using western blotting as well as the RT-PCR 
technique. VEGF expression was estimated in the whole cell 
lysate, as a function of time, at a concentration of 1 µM (FIG. 
7B). Densitometric analysis of western blot images, normal-
ized to ~-actin, showed almost three fold increase after a 2 hr 
treatment. Similar observations were observed in mRNA 
expression ofVEGF, assayed by quantitative RT-PCR (FIG. 
7C). From the ELISA, Western blotting and RT-PCR data it 
was clear that exposure of cells to CNPs induces pro-angio- 60 
genesis via a VEGF-dependent pathway. 
Angiogenesis can be induced either by inducing low levels 
of intracellular reactive oxygen species (ROS) or by control-
ling the intracellular oxygen concentration to the cells. To 
identify the pathways by which CNPs induce the angiogen- 65 
esis, we have analyzed intracellular ROS levels using 2',7'-
dichlorodihydrofluorescein diacetate (DCF) (FIG. 8). No 
with different concentration of CNPs incubated for 24 hr and 
hr. MTT were added to the cell at a final concentration of 1.2 
mM and incubated for 4 hr. Cells were lysed and insoluble 
formazan product was dissolved using buffer (10% SDS, 0.1 
M HCl) and the absorbance 570 nm of each well were mea-
sured using SpectraMax 190 spectrophometer (Molecular 
Devices, Sunnyvale, Calif., USA). Cell proliferation was cal-
culated by absorbing the CNPs treated samples/untreated 
control in percentage. 
Endothelial Tube Formation Assay. 
Growth factor reduced BD matrigel (BD Bioscience) was 
coated on a 96 well plate. 8.0-10.0xl03 endothelial (HUVEC) 
US 8,951,539 Bl 
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cells (passage 4-5) were plated per well. Cells were then 
treated with different concentrations of CNPs (10 run to 10 
µM). A positive control containing 30 ng/ml of rVEGF was 
used and a negative control was included the inhibitor 
2-Methoxyestradiol. The number of tubes formed were cal-
culated after 5 hr hours using brightfield microscopy and 
experiments were included triplicate cultures and carried out 
three times to determine reproducibility. 
CAM Assay. 
The CAM assay was performed as described by Vlahakis et 10 
al in Journal of Biological Chemistry, 282(20, pgs. 15187-
15196 (2007) and by Fang et al in Proceedings of the National 
Academy of Sciences, 97(8), pgs. 3884-3889 (2000). The 
portions of these two articles that describe how a CAM assay 
is performed are incorporated herein by reference. Chicken 15 
eggs were purchased from Charles River Laboratories, Fran-
klin, Conn. and maintained in a humidified 39° C. incubator 
(Lyon Electric, Chula Vista, Calif.). Pellets containing 0.5% 
methylcellulose plus recombinant human VEGF-A (50 ng), 
CNP! (1 µg) or CNP2 (1 µg) were placed onto the CAM of 20 
10-day-old chick embryo. Eggs were subsequently incubated 
at 39° C. and on Day 13 the CAM's were fixed and excised 
and then imaged using a digital camera (Canon PowerShot 6) 
attached to a stereomicroscope (Zeiss, Germany). Angiogen-
esis was quantified by counting the branch points arising from 25 
tertiary vessels from a minimum of 8 specimens from the 
three separate experiments. 
DCFDHA Staining. 
2500 cells/cover slip were seeded on a glass cover slip in a 
6-well cell culture plate and allowed cells to adhere for 24 hrs. 30 
The next day, old media was replaced with fresh media con-
taining CNPs, positive and negative control. Cells were then 
treated with 20 µM DCFDA and incubated for 30 min and 
washed with PBS. After washing cells were fixed under 
chilled methanol (-20° C.) for 8 min. Cells were again 35 
washed twice with PBS followed by incubation with DAPI 
for 8 min. Finally cells were washed and mounted in anti-fade 
mounting media (Calbiochem) and slides were prepared. 
These slides were stored at 4 ° C. until imaging under Leica 
TCS SP5 laser scanning confocal microscope with a 40x 40 
objective lens. 
Pimonidazole Immunostaining. 
Pimonidazole staining was carried out as described by 
Varia et al in Gynecologic Oncology, 71(2), pgs. 270-277 
(1998). The portion of this article that describes how 45 
pimonidazole staining was performed is incorporated herein 
by reference. HUVEC cells were grown on a cover slip over-
night and then treated with 1 µM CNP-I for 0 min (control), 30 
min, 1 hr, and 2 hr. Then pimonidazole (final concentration 
200 µM) was added to the cells and incubated for 45 min and 50 
cells were permeabilized/fixed with ice cold methanol for 10 
min at room temperature and washed thoroughly with saline. 
Fixed cells were then blocked using 3% BSA in saline. Then 
cells were stained with FITC-conjugated monoclonal 
Hypoxyprobe-1 monoclonal antibody 1 (mAbl) (1:100in3% 55 
BSA) for one hr at room temperature and DAPI were used to 
stained the nucleus. Finally, cells were washed and mounted 
12 
(positive control) cells were recovered by BD cell recovery 
kit. NE_PER Nuclear and Cytoplasmic Extraction Kit 
(Thermo) were used to isolate nuclear and cytoplasmic 
extract. Proteins were measured using Bradford assay. An 
equal amount of protein (25 ug) was fractionated by 4-20% 
SDS-PAGE gradient gels and transferred to PVDF mem-
brane. 1 :2000 diluted monoclonal anti-human VEGF and 
HIF 1 a antibody were used as primary antibody, incubated for 
overnight at 4° C. Anti-mouse IgG conjugated with HRP 
(1: 15,000) used as 2ndary antibody, incubated for 1 hr at 
room temperature. A chemiluminescence method was 
adopted for developing the blot. Equal loading was ensured 
by re-probing of the blot using anti-~-actin antibody 
(1: 1000). Densitometry analysis (ImageJ Software) was also 
carried out from the image to have semi quantitative data of 
HIF 1 a nuclear translocation. 
ELISA Assay for VEGF. 
Growth factor reduced BD matrigel (BD Bioscience) was 
coated on a 96 well plate. 8.0-10.0xl03 endothelial (HUVEC) 
cells (passage 4-5) were plated per well as describe in endot-
helial tube formation assay. Then cells were treated with 
different concentration of CNPs and culture media were col-
lected after 8 hr of incubation with nanoparticles. Amount of 
VEGF in culture media were assayed using an ELISA kit 
from Bio Scientific Corporation following the manufactur-
er's instructions. 
RT-PCR. 
Up-regulation or down-regulation of gene expressions 
flowing CNP treatment, if any, related to the angiogenesis 
were analyzed using RTPCR as a function of treatment time 
like 0 hr, 1 hr, 2 hr and 4 hr. Briefly, the total RNA were 
extracted similar as described in the previous section of PCR 
array. Equal quantity of mRNA (0.5 µg) were used for cDNA 
synthesis using !script cDNA synthesis kit (Bio-Rad). Oligo-
nucleotides were designed using Primer3 Software available 
at www.simgene.com. RTPCR was carried out using Bio-Rad 
!Cycler (Biomolecular Science Center) using SYBER green 
dye and the fold up-regulation or down-regulation of each 
gene were calculated from Cr values using GAPDH as an 
internal standard. The oligonucleotides used are listed in 
Table 1. 
TABLE 1 
Human Real-Time PCR Primers listed 5' to 3' 
SEQ ID NO: Sequence 
H0-1 forward SEQ ID NO: 1 ctgagttcatgaggaacmcagaag 
H0-1 reverse SEQ ID NO: 2 tggtacagggaggccatcac 
Trx fmward SEQ ID NO: 3 gcagatcgagagcaagactg 
Trx reverse SEQ ID NO: 4 ctccagaaaattcacccacc 
VEGF forward SEQ ID NO: 5 acacattgttggaagaagcagccc 
VEG F reverse SEQ ID NO: 6 aggaaggtcaaccactcacacaca 
GAPGH forward SEQ ID NO: 7 agtagaggcagggatgatgtt 
GAPDH reverse SEQ ID NO: 8 cmggtatcgtggaaggactc 
The invention has been described above with reference to 
in anti-fade mounting media (Calbiochem) and examined 
under Fluorescence microscope. Using Image J 1.44p soft-
ware (Wayne Rasband, National Institute of Health, USA) 
fluorescence intensity of 20 individual cells/field and differ-
ent fields were estimated for each group and plotted as mean 
and standard deviation. 
60 the accompanying drawings, in which preferred embodi-
ments of the invention are shown. Unless otherwise defined, 
all technical and scientific terms used herein are intended to 
have the same meaning as commonly understood in the art to 
Western Blotting. 
HUVEC cells were seeded on 60 mm petri plates coated 65 
with growth factor reduced BD matrigel (BD biosciences). 
Following CNPs treatment at 0.5 hr, 2 hr and 4 hr or CoC12 
which this invention pertains and at the time of its filing. 
Although various methods and materials similar or equivalent 
to those described herein can be used in the practice or testing 
of the present invention, suitable methods and materials are 
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described. The skilled should understand that the methods 
and materials used and described are examples and may not 
be the only ones suitable for use in the invention. 
In the specification set forth above there have been dis-
closed typical preferred embodiments of the invention, and 
although specific terms are employed, the terms are used in a 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 8 
<210> SEQ ID NO 1 
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 1 
ctgagttcat gaggaacttt cagaag 
<210> SEQ ID NO 2 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 2 
tggtacaggg aggccatcac 
<210> SEQ ID NO 3 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 3 
gcagatcgag agcaagactg 
<210> SEQ ID NO 4 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 4 
ctccagaaaa ttcacccacc 
<210> SEQ ID NO 5 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 5 
acacattgtt ggaagaagca gccc 
<210> SEQ ID NO 6 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
aggaaggtca accactcaca ca ca 
<210> SEQ ID NO 7 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
agtagaggca gggatgatgt t 
14 
descriptive sense only and not for purposes oflimitation. The 
invention has been described in some detail, but it will be 
apparent that various modifications and changes can be made 
within the spirit and scope of the invention as described in the 









US 8,951,539 Bl 
15 16 
-continued 
<210> SEQ ID NO 8 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 8 
ctttggtatc gtggaaggac tc 
The invention claimed is: 
1. A method of promoting angiogenesis in animal tissue, 
the method comprising contacting the tissue with a compo-
15 
sition comprising cerium oxide nanoparticles effective for 
stimulating proliferation of endothelial cells associated with 
the tissue; 
wherein the cerium oxide nanoparticles are spherical with 
a diameter of about 3 nm to about 5 nm; and 
wherein the cerium oxide nanoparticles have a surface and 
a concentration ofCe(3+) greaterthana concentration of 
Ce( 4+) at the surface. 
20 
2. The method of claim 1, wherein the concentration of 25 
cerium oxide nanoparticles in the composition is between 
about 0.5 µM to about 1.5 µM. 
3. The method of claim 1, wherein the concentration of 
cerium oxide nanoparticles in the composition is about 1 µM. 
4. A method of promoting angiogenesis, the method com- 30 
prising administering cerium oxide nanoparticles to a patient 
having a physiological condition that can be remediated by 
increasing endothelial cell proliferation; 
wherein the cerium oxide nanoparticles are spherical with 
a diameter of about 3 nm to about 5 nm; and 35 
wherein the cerium oxide nanoparticles have a surface and 
a concentration ofCe(3+) greaterthana concentration of 
Ce( 4+) at the surface. 
22 
5. The method of claim 4, wherein the cerium nanoparticles 
are provided in a composition at a concentration of between 
about 0.5 µM to about 1.5 µM. 
6. The method of claim 5, wherein a concentration of 
cerium oxide nanoparticles in the composition is about 1 µM. 
7. A method of promoting angiogenesis in a patient having 
a condition that can be remediated by increasing endothelial 
cell proliferation, the method comprising contacting a tissue 
of the patient with cerium oxide nanoparticles in an amount 
sufficient to transiently lower an intracellular oxygen concen-
tration of the tissue, wherein the transient lowering the intra-
cellular oxygen concentration stimulates expression of 
HIFla, promotes proliferation of endothelial cells, and pro-
motes angiogenesis in the tissue; 
wherein the cerium oxide nanoparticles are spherical with 
a diameter of about 3 nm to about 5 nm· and 
wherein the cerium oxide nanoparticles ha~e a surface and 
a concentration of Ce(3+) greaterthan a concentration of 
Ce( 4+) at the surface. 
8. The method of claim 7, wherein theceriumnanoparticles 
are provided in a composition at a concentration of between 
about 0.5 µM to about 1.5 µM. 
9. The method of claim 8, wherein the concentration of 
cerium oxide nanoparticles in the composition is about 1 µM. 
* * * * * 
